Geron Corporation

Geron Corporation said it now expects 2026 RYTELO net revenue toward the midpoint to high end of its previously issued $220 million to $240 million guidance, or approximately $230 million to $240 million. Speaking at the H.C. Wainwright 28th Annual Global Investment Conference, Chief Executive Officer Harout Semerjian said the company reported record quarterly net revenue of $57.5 million, its highest since the July 2024 launch of RYTELO, also known as imetelstat, the first telomerase inhibitor approved for lower-risk myelodysplastic syndromes, with three consecutive quarters of growth. Geron is shifting commercial efforts toward community oncology practices, which account for about 80% of the lower-risk MDS market, and is adding 100 to 200 new RYTELO accounts per quarter, while 34% of its business, measured on a 12-month lookback, already comes from first- and second-line patients. Chief Medical Officer Joseph Eid said National Comprehensive Cancer Network guidelines have been updated twice since launch to position the therapy as a second-line option, and that luspatercept's move to first-line treatment has supported RYTELO uptake. Geron plans to outline its ex-U.S. strategy, particularly for Europe, before year-end without a traditional large-scale country-by-country buildout, and continues the 327-patient IMpactMF Phase 3 trial in relapsed or refractory myelofibrosis, which completed enrollment last September with overall survival as the primary endpoint. The company ended the period with more than $300 million in cash and reiterated 2026 operating-expense guidance of $230 million to $240 million.

Geron Corporation reported second-quarter 2026 revenue of US$57.48 million, up from US$49.04 million a year earlier, and a net loss of US$16.68 million, while issuing its first full-year 2026 RYTELO net product revenue guidance of US$220 million to US$240 million. First-half revenue reached US$109.32 million and the first-half net loss narrowed to US$20.32 million. The company also filed a US$6.03 million common stock shelf registration for 4,500,000 shares tied to an employee stock ownership plan. The reiterated guidance sharpens focus on the launch trajectory of Geron's sole commercial therapy, RYTELO, as the company remains dependent on a single drug and faces ongoing cash needs.

Several biotech companies posted sharp gains on Wednesday, led by Attovia Therapeutics' 28% surge on its Nasdaq debut and American Well's 25% jump after narrowing its quarterly loss. Attovia priced its IPO at $17 per share and closed at $21.90, while American Well reported a net loss of $9.6 million, or $0.59 per share, down from $19.5 million, or $1.24 per share, a year earlier, though revenue fell to $52.0 million from $70.9 million. Perrigo swung to a net income of $74.5 million, or $0.53 per share, from a loss of $8.4 million, or $0.06 per share, despite a slight revenue dip to $1.02 billion. UroGen Pharma climbed over 16% after total revenue more than doubled to $72.5 million, driven by its bladder cancer drug ZUSDURI, and its net loss narrowed to $14.4 million from $49.9 million. Geron rose 21% as net product revenue increased to $57.5 million from $49.0 million, fueled by higher RYTELO sales, and it forecast full-year RYTELO revenue of $220 million to $240 million.

Geron Corporation has appointed Chinmaya Rath as its new Chief Business Officer. Rath brings over 25 years of biopharma leadership experience, including a significant tenure at Novartis where he led enterprise-wide strategic initiatives such as the integrations of GSK Oncology and Alcon. Most recently, he served as Head of Pharma Solutions at Cellworks and Chief Business Officer at GlycoMimetics. Geron's President and CEO Harout Semerjian stated that Rath's appointment underscores the company's dedication to maximizing the value of RYTELO globally and building a leading hematology company. Rath highlighted RYTELO's best-in-class profile and strong commercial performance in lower-risk myelodysplastic syndromes as positioning Geron for continued growth.